simipex pramipexole dihydrochloride monohydrate 1.5 mg tablet blister pack
arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.
simipex pramipexole dihydrochloride monohydrate 0.5 mg tablet blister pack
arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.5 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.
ppramipexole an pramipexole dihydrochloride monohydrate 0.125 mg tablet blister pack
southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -
pramipexole an pramipexole dihydrochloride monohydrate 1.5 mg tablet blister pack
southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -
pramipexole an pramipexole dihydrochloride monohydrate 0.5 mg tablet blister pack
southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -
simpral pramipexole dihydrochloride monohydrate 1 mg tablet blister pack
alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: hyprolose; colloidal anhydrous silica; crospovidone; magnesium stearate; pregelatinised maize starch; sodium citrate; mannitol - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.
pramipexole dihydrochloride tablet
zydus pharmaceuticals usa inc. - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.125 mg - pramipexole dihydrochloride tablets are indicated for the treatment of parkinson's disease. pramipexole dihydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). none. risk summary there are no adequate data on the developmental risk associated with the use of pramipexole in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexole (0.1, 0.5, or 1.5 mg/kg/day) to pregna
pramipexole xr gp pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack
arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: hypromellose; calcium hydrogen phosphate; magnesium stearate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.
pramipexole xr gp pramipexole dihydrochloride monohydrate 0.375 mg modified release tablet blister pack
arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.375 mg - tablet, modified release - excipient ingredients: hypromellose; calcium hydrogen phosphate; silicon dioxide; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.
simipex xr pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack
arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; silicon dioxide; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.